Updated Jul 16, 2026
Silverman Joshua has filed 2 SEC Form 4 filings across 2 companies in the last 90 days — buying. Lifetime open-market purchases: $80K. Historical track record: 1/5 stars across 3 tracked purchases.
Joshua Silverman is an executive in the biotechnology sector, currently serving as Executive Chairman and CEO of PharmaCyte Biotech, Inc. He has held various leadership roles across multiple companies, focusing on developing cellular therapies for cancer and diabetes.
| Role | Director |
|---|---|
| Notability | 20/100 |
InsiderAlpha computes a forward-return-based score for every insider with enough Form 4 purchase history. The metrics below reflect realised performance after each tracked open-market purchase.
| InsiderAlpha rating | ★☆☆☆☆ (1/5) |
|---|---|
| Total purchases tracked | 3 |
| Purchases with forward-return data | 3 |
| 30-day win rate | 0% |
| 90-day win rate | 0% |
| Avg 5-day return | +1412.06% |
| Avg 30-day return | -907.23% |
| Avg 90-day return | -1117.50% |
| Best 30-day return | -719.16% |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-06-05 | PTPI | Petros Pharmaceuticals, Inc. | A — Grant or award | 4.38M | $0.00 | |
| 2026-04-15 | QCLS | Q/C TECHNOLOGIES, INC. | A — Grant or award | 162.2K | $0.00 | |
| 2026-01-07 | PMCB | PharmaCyte Biotech, Inc. | P — Open-market purchase | 40.0K | $0.83 | $33K |
| 2026-01-07 | PMCB | PharmaCyte Biotech, Inc. | P — Open-market purchase | 30.0K | $0.79 | $24K |
| 2026-01-07 | PMCB | PharmaCyte Biotech, Inc. | P — Open-market purchase | 30.0K | $0.78 | $23K |
| 2025-12-12 | PMCB | PharmaCyte Biotech, Inc. | F — Tax withholding / forfeiture | 258.8K | $1.02 | $264K |
| 2025-12-12 | PMCB | PharmaCyte Biotech, Inc. | A — Grant or award | 575.0K | $0.00 | |
| 2025-11-15 | QCLS | Q/C TECHNOLOGIES, INC. | A — Grant or award | 91.4K | $0.00 | |
| 2025-10-03 | QCLS | Q/C TECHNOLOGIES, INC. | A — Grant or award | 8.6K | $0.00 | |
| 2025-08-06 | TAOX | TAO Synergies Inc. | F — Tax withholding / forfeiture | 40.0K | $7.23 | $289K |
| 2025-08-06 | TAOX | TAO Synergies Inc. | A — Grant or award | 100.0K | $0.00 | |
| 2025-06-30 | TAOX | TAO Synergies Inc. | F — Tax withholding / forfeiture | 16.8K | $7.85 | $132K |
| 2025-06-30 | TAOX | TAO Synergies Inc. | A — Grant or award | 41.9K | $0.00 | |
| 2024-12-02 | FABC | Fabric.AI, Inc. | A — Grant or award | 146.1K | $0.00 | |
| 2024-12-02 | FABC | Fabric.AI, Inc. | D — Derivative transaction | 6.2K | $0.00 |
Joshua Silverman is an executive in the biotechnology sector, currently serving as Executive Chairman and CEO of PharmaCyte Biotech, Inc. He has held various leadership roles across multiple companies, focusing on developing cellular therapies for cancer and diabetes.…
2 primary Form 4 filings in the last 90 days, covering 2 companies.
Recorded transactions: 3 open-market purchases ($80K) and 0 open-market sales () across all tracked filings.
Across 3 tracked purchases, Silverman Joshua averaged -907.2% avg 30-day return with a 0% 30-day win rate. InsiderAlpha rates the track record at 1/5 stars.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Silverman Joshua profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.